A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis
JAAD International（2022）
摘要
The results were generally consistent with those of previous reports; no new safety risks were detected.
更多查看译文
关键词
atopic dermatitis,clinical trial,eczema,Janus kinase inhibitors,safety,topical corticosteroids,upadacitinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要